Mazdutide

Mazdutide is a dual agonist that activates both the GLP-1 and glucagon receptors, built on the framework of the natural gut hormone oxyntomodulin.

The GLP-1 arm provides the familiar appetite suppression and insulin effects, while the glucagon arm is thought to raise energy expenditure and improve how the liver handles fat — a two-lever approach to weight and metabolic disease.

It's engineered for once-weekly dosing and is in late-stage development, particularly in China. It remains investigational rather than broadly approved.